Endo Pharmaceuticals Inc. and GlaxoSmithKline LLC agreed to settle lawsuits accusing the drugmakers of hiding the health risks of their testosterone-boosting drugs marketed to middle-aged men, according to court filings.
The terms of the tentative deal weren’t disclosed Feb. 23, but the accord would resolve more than 1,300 suits filed by men who blame the companies’ testosterone products for causing potentially fatal blood clots.
U.S. District Judge Matthew Kennelly in Chicago, overseeing more than 6,000 testosterone cases consolidated for pre-trial information exchanges and test trials, is putting on hold all litigation against Endo, its Auxilium unit and London-based GSK while the details of the settlement are worked out. That means an April 6 trial against Endo and Auxilium over its Testim gel is off the court’s schedule, the court filings show.
“The parties are negotiating the terms of a potential settlement, subject to certain contingencies and conditions, Heather Zoumas Lubeski, a spokeswoman for Endo and Auxilium, said recently in an emailed statement. “The settlement will not involve any admission of wrongdoing or liability.’’
The suits also contend the companies violated federal law through their overly aggressive marketing tactics.